Nonvitamin K-dependent oral anticoagulant agents (NOACs) are currently recommended for
patients with atrial fibrillation at risk for stroke. As a group, NOACs significantly reduce …

Introduction Stroke is one of the leading causes of mortality and morbidity globally. Atrial
fibrillation (AF) is the most common sustained cardiac arrhythmia. It is set to reach epidemic …

Background We aimed to assess the safety of edoxaban in combination with P2Y12
inhibition in patients with atrial fibrillation who had percutaneous coronary intervention (PCI) …

Highlights•Around half of the new molecular entities approved by the US Food and Drug
Administration are pharmaceutical salts.•The drug-approval database contains 61 …

Background Anticoagulation in patients with malignancy and atrial fibrillation is challenging
because of enhanced risks for thrombosis and bleeding and the frequent need for invasive …

A large body of evidence suggests that not only direct anticoagulant effects but also major
bleeding events and stroke prevention depend on plasma concentrations of direct oral …

Direct oral anticoagulants (DOACs) are a more manageable alternative than vitamin K
antagonists (VKAs) to prevent stroke in patients with nonvalvular atrial fibrillation and to …

Direct oral anticoagulants (DOAC) have shown an upward prescribing trend in recent years
due to favorable pharmacokinetics and pharmacodynamics without requirement for routine …

Bariatric surgery may alter the absorption, distribution, metabolism, or elimination
(disposition) of orally administered drugs via changes to the gastrointestinal tract anatomy …

The direct oral anticoagulants (DOACs), dabigatran, rivaroxaban, apixaban, and edoxaban,
are becoming the most commonly prescribed drugs for preventing ischemic stroke in …